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AbstrAct
background Observational studies suggest that the 
Manchester Acute Coronary Syndromes (MACS) decision 
rule can effectively ’rule out’ and ’rule in’ acute coronary 
syndromes (ACS) following a single blood test. In a pilot 
randomised controlled trial, we aimed to determine 
whether a large trial is feasible.
Methods Patients presenting to two EDs with 
suspected cardiac chest pain were randomised to receive 
care guided by the MACS decision rule (intervention 
group) or standard care (controls). The primary efficacy 
outcome was a successful discharge from the ED, 
defined as a decision to discharge within 4 hours of 
arrival providing that the patient did not have a missed 
acute myocardial infarction (AMI) or develop a major 
adverse cardiac event (MACE: death, AMI or coronary 
revascularisation) within 30 days. Feasibility outcomes 
included recruitment and attrition rates.
results In total, 138 patients were included between 
October 2013 and October 2014, of whom 131 (95%) 
were randomised (66 to intervention and 65 controls). 
Nine (7%) patients had prevalent AMI and six (5%) 
had incident MACE within 30 days. All 131 patients 
completed 30-day follow-up and were included in the 
final analysis with no missing data for the primary 
analyses. Compared with standard care, a significantly 
greater proportion of patients whose care was guided 
by the MACS rule were successfully discharged within 
4 hours (26% vs 8%, adjusted OR 5.45, 95% CI 1.73 
to 17.11, p=0.004). No patients in either group who 
were discharged within 4 hours had a diagnosis of AMI 
or incident MACE within 30 days (0.0%, 95% CI 0% to 
20.0% in the intervention group).
conclusions In this pilot trial, use of the MACS rule led 
to a significant increase in safe discharges from the ED 
but a larger, fully powered trial remains necessary. Our 
findings seem to support the feasibility of that trial.
trial registration number ISRCTN 86818215.
research Ethics committee reference 13/
NW/0081.
UKcrN registration ID 14334.
bAcKgroUND
Current approaches to ‘ruling out’ acute coronary 
syndromes (ACS) rely on serial biomarker testing 
over a number of hours. The Manchester Acute 
Coronary Syndromes (MACS) decision rule is 
designed to enable clinicians in the ED to ‘rule in’ and 
‘rule out’ ACS following a single blood test.1 2 The 
MACS rule, which was derived by logistic regression, 
incorporates eight variables (table 1). The rule esti-
mates the probability that a patient either has AMI or 
will develop a major adverse cardiac event (MACE) 
within 30 days. Based on that probability, patients are 
assigned to one of four risk groups, each of which 
has a recommended destination for the patient: ‘very 
low risk’ (home); ‘low risk’ (low dependency obser-
vation ward); ‘moderate risk’ (acute inpatient area; 
intermediate dependency); and ‘high risk’ (specialist 
cardiology ward or high-dependency environment). 
In two external validation studies including a total of 
1245 patients, the MACS rule successfully risk strat-
ified patients and identified a group potentially suit-
able for immediate discharge.1 3 While there are also 
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Key messages
What is already known on this subject?
 ► Observational research has shown that the 
Manchester Acute Coronary Syndromes 
(MACS) decision rule could be used to safely 
reduce hospital admissions and make judicious 
use of inpatient resources by ‘ruling out’ and 
‘ruling in’ acute coronary syndromes following 
a single blood test in the ED. We do not yet 
know how the MACS rule will perform when 
used to guide the management of patients in 
real-life practice.
What this study adds?
 ► Our findings seem to suggest that a larger 
trial will be feasible to conduct, although 
we will need to ensure adequate support to 
achieve a sufficient recruitment rate at each 
trial centre. In this small pilot randomised 
controlled trial, patients whose care was 
guided by the MACS rule were more likely to 
be successfully discharged within 4 hours of 
arrival than patients receiving standard care. 
None of those patients had a major adverse 
cardiac event within 30 days (part of the 
primary efficacy outcome) or within 6 months 
(secondary outcome), although a larger trial is 
required to provide greater statistical power 
for that analysis.
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table 1 Components of the MACS decision rule
Variable Format
a. High-sensitivity cardiac troponin T (ng/L) Continuous variable
b. Heart type fatty acid binding protein (ng/mL) Continuous variable
c. Acute ECG ischaemia (treating clinician’s interpretation) Dichotomous
d. Sweating observed by the treating clinician Dichotomous
e. Vomiting in association with the presenting symptoms Dichotomous
f. Systolic BP <100 mm Hg on arrival Dichotomous
g. Worsening (or crescendo) angina Dichotomous
h. Pain radiating to the right arm or shoulder Dichotomous
The MACS rule estimates the probability (p) of acute coronary syndromes as follows 
(rounded values are presented): p=1/(1+e-(0.068a + (0.17(b -0.28)/1.35) + 1.75c + 1.85d + 1.72e + 
1.46f + 0.92g + 0.87h -4.83)). For dichotomous variables, a value of ‘1’ is entered for ‘yes’ 
and ‘0’ for ‘no’. The constants presented here assume use of the Roche Elecsys hs-
cTnT assay and the Randox Laboratories immunoturbidimetric H-FABP assay.
H-FABP, heart type fatty acid binding protein; hs-cTnT, high sensitivity cardiac 
troponin T; MACS, Manchester Acute Coronary Syndrome.
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other promising early ‘rule out’ strategies, we chose to evaluate 
MACS as it can both ‘rule in’ and ‘rule out’ ACS with a single 
blood test at the time of arrival in the ED.
Evaluating new diagnostic technology in observational 
research alone has important limitations. It is possible that any 
beneficial effects will be diluted when rules are implemented in 
practice because clinicians do not abide by the recommendations. 
Unanticipated effects, such as rebound overuse of resources in 
patients who cannot have ACS ‘ruled out’, have previously been 
reported and have meant that apparently safe pathways are not 
cost-effective.4 The next phase in the evaluation of the MACS 
rule is therefore to evaluate its impact in clinical practice. This 
can be robustly accomplished in a randomised controlled trial 
(RCT). The value of a rigorous feasibility trial, in which trial 
design and procedures are evaluated before embarking on a full-
scale trial, is increasingly recognised.
We therefore aimed to evaluate the feasibility of running a 
multicentre RCT to compare the use of the MACS rule to stan-
dard practice. While recognising that the analysis was likely to be 
underpowered in this pilot trial, we also sought to evaluate the 
efficacy of the MACS rule as a tool to increase the proportion 
of patients successfully discharged within 4 hours of arrival in 
the ED.
MEthoDs
Design and setting
We conducted a prospective, pragmatic, pilot RCT at two 
centres in Greater Manchester, UK (Manchester Royal Infir-
mary and Salford Royal Infirmary). Written informed consent 
was obtained from all participants and the study was approved 
by the research ethics committee (reference 13/NW/0081).
Participants
We included adults (>18 years) presenting to the ED with pain, 
discomfort or pressure in the chest, epigastrium, neck, jaw or 
upper limb without an apparent non-cardiac source (compatible 
with the American Heart Association case definitions,5 which the 
treating physician believed warranted investigation for possible 
ACS. We excluded patients with peak symptoms occurring 
>24 hours prior to presentation; those who could not have been 
discharged if ACS had been ruled out; patients with definite 
ST elevation myocardial infarction; those with no capacity to 
provide written informed consent; those unable to communicate 
in English language unless translation services were available; 
and prisoners.
Intervention and randomisation
Consenting participants were randomly allocated to the inter-
vention or control group in a 1:1 ratio using a central, Inter-
net-based randomisation service managed by Glasgow Clinical 
Trials Unit. Randomisation was stratified by trial centre and 
MACS rule risk group. Admission blood samples were tested 
for high sensitivity cardiac troponin T (hs-cTnT; Roche Diag-
nostics Elecsys, 99th percentile 14 ng/L, coefficient of variation 
<10% at 13 ng/L) and heart type fatty acid binding protein 
(H-FABP; Randox Laboratories immunoturbidimetric assay). 
Clinical data were recorded contemporaneously by the treating 
clinician using a bespoke case report form, and later trans-
ferred to an electronic case report form by research nurses or 
investigators.
In both groups, the required data for calculation of the 
MACS rule outcome were entered prior to randomisation using 
an online tool created by Glasgow Clinical Trials Unit. To avoid 
contamination between trial groups, the outcome of the MACS 
rule calculation was only revealed for patients randomised to 
the intervention group. Patients randomised to this group had 
their care guided by the MACS decision rule. The website calcu-
lated the estimated probability of MACE, stratified patients into 
four risk groups and recommended the following disposition for 
patients: ‘very low risk’ patients could be discharged; ‘low risk’ 
patients should undergo serial troponin testing in either an ED 
observation ward or (if that is not available) an acute medical 
unit; ‘moderate risk’ patients should undergo serial troponin 
testing in an acute medical unit; and ‘high-risk’ patients should 
be referred to a cardiologist and managed in a specialist or 
high-dependency environment. As part of the follow-up for this 
trial, all participants who were discharged from the ED without 
hs-cTnT sampling at least 12 hours after peak symptoms were 
given a follow-up appointment within 72 hours, at which point 
hs-cTnT concentration was again measured. This ensured that 
we were able to detect any missed prevalent AMIs in this group.
Care of the control group was guided by local ED guidelines 
for the management of suspected acute coronary syndromes, 
which were consistent with contemporaneous national guid-
ance.6 At both trial centres, this required measuring hs-cTnT on 
arrival and 12 hours after peak symptoms.
In this pragmatic trial, patients in both groups who presented 
>12 hours after peak symptoms could have AMI ‘ruled out’ using 
a single hs-cTnT concentration, in accordance with contempo-
rary national guidance at the time of the trial.6 This meant that, 
in both groups, clinicians could discharge late presenting patients 
following a single troponin test if deemed clinically appropriate. 
As an example, a patient in the intervention group could have 
been identified as being at ‘moderate risk’ with a suggestion for 
serial troponin testing in an acute medical ward. If, however, 
the admission troponin sample was drawn >12 hours after peak 
symptoms, the need for serial troponin sampling was obviated, 
and the patient could still be discharged if the treating clinician 
deemed this to be clinically appropriate.
Follow-up
Participants were followed up after 30 days, 3 months and 6 
months by electronic chart review and either telephone, email or 
letter. At each visit, participants completed a structured question-
naire to determine clinical events, healthcare resource use and 
EQ-5D. Each participant was also asked to complete a modified 
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Figure 1 Participant flow diagram.
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Group Health Association of America (GHAA) questionnaire to 
assess patient satisfaction after 30 days and 6 months.
outcomes
The primary efficacy outcome was successful early discharge, 
defined as a decision to discharge the patient from hospital 
within 4 hours of arrival (specified a priori and based on the 
process target within the UK), excluding those patients who 
either (1) had a missed diagnosis of AMI or (2) experienced 
MACE within 30 days. MACE included death (all cause), inci-
dent AMI or coronary revascularisation procedures. Secondary 
outcomes included1: the incidence of MACE after 30 days, 3 
months and 6 months and2 length of initial hospital stay.
Feasibility outcomes included: (1) the number of eligible 
patients approached; (2) the proportion of approached patients 
randomised; (3) attrition (including both failure to complete the 
trial protocol and loss to follow-up); (4) completeness of data 
collection; and (5) patient satisfaction. We also further explored 
the feasibility of the trial processes to clinicians and participants 
using qualitative methods, which we plan to report separately.
Measuring outcomes
The dates and times of admission, decision to discharge and actual 
discharge were determined from electronic hospital records. The 
time to decision to discharge was calculated as the time between 
arrival in the ED and the time of actual discharge unless it had 
been documented that the patient was medically fit for discharge 
at an earlier stage but discharge was delayed pending other factors 
(for example, waiting for transport home). The case report form, 
which was completed by the treating clinician, asked clinicians to 
record the time of this decision.
Death and coronary revascularisation were determined at 
follow-up from review of a national mortality database (NHS 
Spine), hospital records (including any relevant investigation or 
procedure reports) and patient self-report. The diagnosis of AMI 
was adjudicated by two independent investigators in accordance 
with the third universal definition of myocardial infarction7 and 
with reference to all relevant investigations (including the ECG, 
cardiac troponin concentrations and follow-up data including 
the findings of any relevant imaging investigations) but blinded 
to the MACS rule. In order to fulfil the diagnosis of AMI, 
patients were required to have a rise and/or fall of hs-cTnT with 
at least one level above the 99th percentile (14 ng/L). An absolute 
change of 9.2 ng/L on serial hs-cTnT sampling was deemed to 
demonstrate a rise and/or fall.8 Of note, to avoid verification 
bias, reference standard late troponin testing was undertaken in 
all patients. Patients who were discharged early as part of this 
trial still underwent late troponin sampling as detailed above, 
on an outpatient basis. This enabled us to be conf ident about 
the prevalence of missed AMI in the trial. The patient group we 
consulted when designing this trial fed back that this element of 
the design was important and desirable.
Patient satisfaction was measured at follow-up after 30 days using 
a modified GHAA consumer satisfaction survey.9 The number of 
eligible patients approached was determined from contempora-
neous screening records maintained by research staff.
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table 2 Baseline characteristics of participants
characteristics All, n=131 Intervention group, n=66 control group, n=65
Centre, n (%) Central Manchester
Salford
113 (86)
18 (14)
57 (86)
9 (14)
56 (86)
9 (14)
Age, mean (SD) 58.9 (16.3) 60.8 (14.8) 56.9 (17.5)
Female sex, n (%) 52 (40) 28 (42) 24 (37)
Ethnic origin, n (%) British White 87 (66) 43 (65) 44 (68)
Asian Pakistani 12 (9) 5 (8) 7 (11)
Asian Other 7 (5) 5 (8) 7 (11)
Irish White 5 (4) 3 (5) 2 (3)
Black Caribbean 4 (3) 2 (3) 2 (3)
Other 12 (9) 7 (11) 5 (8)
Does not wish to answer 4 (3) 1 (2) 3 (5)
Previous myocardial infarction, n (%) 44 (34) 20 (30) 24 (37)
Previous history of angina, n (%) 47 (36) 25 (38) 22 (34)
Previous percutaneous coronary intervention, n (%) 31 (24) 18 (27) 13 (20)
Previous coronary artery bypass graft, n (%) 7 (5) 2 (3) 5 (8)
Previous history of hypertension, n (%) 56 (43) 29 (44) 27 (42)
Previous history of hyperlipidaemia, n (%) 44 (34) 23 (35) 21 (32)
Type 1 diabetes, n (%) 2 (2) 1 (2) 1 (2)
Type 2 diabetes, n (%) 24 (18) 14 (21) 10 (15)
Median time from symptom onset (IQR) 45.00 (15.00 to 120.00) 35.00 (10.00 to 150.00) 60.00 (20.00 to 120.00)
MACS rule risk group, n (%) Very low risk 33 (25) 16 (24) 17 (26)
Low risk 36 (27) 18 (27) 18 (28)
Moderate risk 57 (44) 29 (44) 28 (43)
High risk 5 (4) 3 (5) 2 (3)
table 3 Incidence of the primary and secondary efficacy outcomes stratified by trial group
outcome
total
n=131
Intervention
n=66
control
n=65 or (95% cI),p value
Early discharge within 4 hour without prevalent AMI or incident
MACE at 30 days, n (% (95% CI))
22 (17%) 17 (26%) 5 (8%) Unadjusted
Adjusted*
4.16 (1.43 to 12.09), p0.009
5.45 (1.73 to 17.11), p=0.004
Prevalent AMI, n (%) 9 (7) 3 (5) 6 (9) 0.47 (0.11 to 1.96), p=0.30
Incident MACE at 30 days†, n (%) 6 (5) 3 (5) 3 (5) 0.98 (0.19 to 5.06), p=0.985
Incident MACE at 90 days†, n (%) 9 (7) 5 (8) 4 (6) 1.36 (0.35 to 5.34), p=0.656
Incident MACE at 180 days†, n (%) 11 (8) 6 (9) 5 (8) 1.30 (0.37 to4.56), p=0.678
Hospital length of stay (median, IQR) 1 (0–1) 1 (0–1) 1 (0–1) p=0.54‡
Patient satisfaction (mean score, SD) 3.8 (1.0) 3.8 (1.0) 3.8 (1.1) p=0.80‡
Re-attendance at an ED, n (%) 18 (23) 10 (23) 8 (23) p=0.97
Any further investigation for heart disease within 30 days, n (%) 27 (21) 15 (23) 12 (18) p=0.55
Myocardial perfusion imaging (thallium scan) within 30 days, n (%) 8 (28) 3 (19) 5 (38) p=0.24
Stress ECG within 30 days, n (%) 1 (4) 1 (7) 0 (0) p=0.34
Coronary angiography within 30 days, n (%) 9 (32) 4 (27) 5 (38) p=0.51
*Adjusted for trial centre, age, gender, cardiovascular risk factors and history of prior coronary artery disease. This is the prespecified primary analysis.
†Incident death, AMI or coronary revascularisation (not including prevalent AMI). NB, no patients who were discharged early developed a MACE.
‡Mann-Whitney U test.
MACE, major adverse cardiac event.
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statistical analysis
All statistical analyses were specified in the protocol and described 
in a detailed statistical analysis plan prior to the final unblinded 
analysis, which was undertaken by the trial statisticians (AM 
and CB). We calculated the OR for achie ving the primary effi-
cacy outcome by logistic regression with the primary outcome 
as the dependent variable. An initial binary logistic regression 
analysis was undertaken to yield a simple unadjusted OR with a 
95% CI. For the primary analysis (from which conclusions are 
drawn), important covariates were also entered into the model 
(age, gender, trial centre, MACS risk group, cardiovascular risk 
factors and a prior history of coronary artery disease). Similarly, 
the absolute rate of MACE (secondary outcome) at 30 days, 
3 months and 6 months was compared between groups using 
logistic regression. Length of stay and patient satisfaction data 
were compared between randomised groups using the Mann-
Whitney U test. Finally, we calculated the incidence of MACE 
at 30 days, 90 days and 180 days stratified by MACS rule risk 
group in all participants. Statistical analyses were undertaken 
using SAS for Windows V.9.3. As this is a feasibility study, no 
formal sample size calculation was undertaken but we aimed to 
evaluate recruitment rate over a fixed period.
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table 4 Incidence of MACE stratified by MACS rule risk group in all 
patients
Very low 
risk
Low
risk
Moderate 
risk
high 
risk
Total number of patients (%) in 
group
33 (25.2) 36 (27.5) 57 (43.5) 5 (3.8)
MACE at 30 days, n (%) 0 (0) 0 (0) 4 (7) 2 (40)
MACE at 90 days, n (%) 0 (0) 1 (3) 6 (11) 2 (40)
MACE at 180 days, n (%) 0 (0) 1 (4) 8 (18) 2 (40)
MACE, major adverse cardiac event; MACS, Manchester Acute Coronary Syndromes.
original article
rEsULts
Of 283 patients screened, 138 were eligible and included 
between 29 October 2013 and 24 January 2014 (Manchester) 
and between 24 July 2014 and 10 October 2014 (Salford). 
Figure 1 shows a participant flow diagram detailing the patients 
screened, eligible, included, randomised and followed up. Base-
line characteristics of participants are shown in table 2.
Feasibility outcomes
Of the 138 included patients, 131 (95%) were randomised and 
included in the analysis. The data were 100.0% complete for all 
randomised patients with regard to the variables incorporated 
in the MACS rule, patient symptoms, history, physical examina-
tion, clinician gestalt, disposition from the ED and follow-up for 
clinical events after 30 days. All patients had sufficient follow-up 
data for evaluation of the primary outcome at 30 days. A total 
of 119 (91%) patients completed the patient satisfaction ques-
tionnaire after 30 days and there were no significant differences 
in patient satisfaction between the groups (table 3 and online 
supplementary table 1). At 6 months, 107 (82%) patients had 
completed follow-up.
Primary efficacy outcome
In total, 17 (26%) patients in the intervention group met the 
primary outcome of successful discharge from the ED within 
4 hours without MACE after 30 days compared with 5 (8%) 
patients in the control group. This yielded an unadjusted OR 
of 4.16 (95% CI 4.16 to 12.09, p=0.009) and an adjusted OR 
of 5.45 (95% CI 1.73 to 17.11, p=0.004), indicating that a 
significantly greater proportion of patients in the intervention 
group achieved the primary outcome. None of the patients in 
either group who were discharged within 4 hours had a diag-
nosis of AMI or incident MACE within 30 days. Thus, in the 
intervention group, 0 (0.0%, 95% CI 0% to 20.0%) patients 
who were discharged from the ED developed MACE within 
30 days.
In the intervention group, 16 (24.2%) patients had been iden-
tified as being at ‘very low risk’ by the MACS rule, of whom 
12 (75.0%) were actually discharged within 4 hours of arrival. 
One patient in the ‘very low risk’ group was discharged directly 
from the ED but did not meet the primary outcome as the time 
of discharge was recorded as being 4.4 hours after arrival. Of 
the three remaining ‘very low risk’ patients in the intervention 
group who were not discharged within 4 hours, in two cases 
this was caused by a delay to obtaining H-FABP results from the 
laboratory (both patients were sent to in patient areas to await 
results). In the remaining case, the patient had been discharged 
home within 4 hours of arrival but an electronic hospital system 
had recorded the disposition as the ED observation ward rather 
than ‘home’. While this appears to have been an administrative 
error, we made a conservative assumption that the patient had 
not been discharged directly from the ED and therefore did not 
meet the primary outcome.
Five (7.6%) patients in the intervention group were 
discharged from the ED despite not being in the ‘very low 
risk’ group, three of whom were ‘low risk’ and two of whom 
were ‘moderate risk’ according to the MACS rule. All of these 
patients had presented late (>12 hour) after symptom onset. 
While this remains entirely in accordance with acceptable 
practice during the study period, we ran a conservative sensi-
tivity analysis considering that patients in the intervention 
group who were discharged early despite not being in the ‘very 
low’ risk group did not meet the primary outcome. With this 
assumption, the proportion of patients meeting the primary 
outcome of successful discharge remained significantly higher 
in the intervention group (12 (18%) vs 2 (3%), OR 7.0, 95% CI 
1.5 to 32.7, p=0.013).
secondary efficacy outcomes
Noting the important fact that no formal power calculation had 
been conducted and that this pilot trial included a relatively 
small number of patients, we did not detect any significant 
differences in the incidence of MACE at 30 days (5% vs 5%, 
p=0.985), 3 months (8% vs 6%, p=0.656) or 6 months (9% vs 
8%, p=0.678) between groups (table 3). Similarly, we did not 
detect any apparent differences in length of hospital stay, ED 
re-attendance or further investigation for coronary artery disease 
(summarised in table 3). The incidence of MACE stratified by 
MACS rule risk group among all patients is shown in Table 4. 
Among patients in the MACS rule ‘very low risk group’, the 
mean length of stay was 2.0 hours (SD 6.9 hours) in the inter-
vention group versus 10.5 hours (SD 12.3 hours) in the control 
group (see online supplementary table 2).
DIscUssIoN
A number of our findings tend to suggest that a larger multicentre 
RCT will be feasible. For example, this study has demonstrated 
that a satisfactory proportion of patients proceeded to rando-
misation (95%) and completed 30-day follow-up for evaluation 
of the primary outcome (100%). We observed no missing data 
for important variables. The recruitment rate at the Manchester 
site (120 participants in 12 weeks) met the prespecified expected 
rate of 10 participants per week. We have, however, detected 
issues that will need to be addressed to optimise delivery of such 
a trial. The recruitment rate at the Salford site was much slower 
than anticipated (18 participants in 11 weeks or 1.6 participants 
per week). The reasons for this discrepancy will be explored 
through qualitative analyses that will be presented separately.
In this pilot trial, we also found that the use of the MACS rule 
in real-life clinical settings led to a significant reduction in unnec-
essary hospital admissions. Over one quarter (26%) of patients 
in the intervention group were successfully discharged without a 
missed AMI or incident MACE within 30 days, compared with 
8% in the control group, which was highly statistically signifi-
cant (p=0.004).
The detection of a significant increase in the proportion of 
patients successfully discharged within 4 hours of arrival in the 
ED, however, is unlikely to be sufficient to change practice. 
Clinicians are likely to require robust evidence that the incidence 
of MACE is sufficiently low in discharged patients to change 
their practice. In this pilot trial, the upper bound of the 95% CI 
for the incidence of MACE among discharged patients in this 
trial was as high as 20%. A larger trial is therefore still required 
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to obtain a more precise estimate of the incidence of MACE 
among patients who are discharged early.
Limitations
Aside from the requirement for a larger study, it is important to 
note that the MACS rule has to date been validated with one 
troponin assay (hs-cTnT) and incorporates H-FABP, which is 
not currently used in routine clinical practice. There remains a 
need for published validation of MACS with different troponin 
assays. Evaluation of the recently refined ‘troponin-only MACS 
rule’, which does not require H-FABP measurement, is also still 
required.10
Future directions
In this rapidly changing field, it is now prudent to consider the 
appropriate comparator for a definitive RCT of the MACS rule. 
In our study, standard care included cardiac troponin testing 
12 hours after symptom onset, whereas new national recommen-
dations allow for AMI to be ‘ruled out’ with two blood tests taken 
3 hours apart, regardless of the time from symptom onset.11 As 
there is a 4-hour process target in the UK, it is unlikely that 
use of this comparator would lead to different results than we 
observed. However, there are also emerging alternatives to the 
MACS rule that could ‘rule out’ ACS in some patients with a 
single blood test. The HEART score (History, ECG, Age, Risk 
Factors, Troponin), for example, uses elements of the patient’s 
history, ECG findings, age, risk factors for coronary artery 
disease and initial coronary artery disease to identify a group 
of patients that could be immediately discharged.12 AMI could 
potentially also be ‘ruled out’ in patients with hs-cTnT concen-
trations below the limit of detection of the assay and no ECG 
ischaemia.13–16 Other tools, such as the Emergency Department 
Assessment of Chest Pain Score (ED-ACS) or bespoke algorithms 
to rule out AMI with hs-cTnT testing alone, could be used to 
discharge more patients following serial troponin testing after 
1 to 2 hours.17 18 Some of these alternatives have already been 
evaluated in RCTs. Two-hour troponin sampling used alongside 
the thrombolysis in myocardial infarction risk score has been 
shown to increase the proportion of patients discharged from 
the ED within 6 hours compared with standard care.19 A subse-
quent trial showed that use of the ED-ACS score could achieve 
a similar proportion of early discharges.17 Three-hour troponin 
sampling used alongside the HEART score has also been shown 
to increase the proportion of early discharges in a trial from the 
USA.20
With several potential comparators, it seems prudent to under-
take direct comparisons of the diagnostic accuracy of alternative 
strategies, which may be most efficiently achieved through obser-
vational studies. The findings of such head-to-head comparisons 
would then inform the design of future large trials.
A RCT remains important as the MACS rule may have 
important advantages over other strategies. For example, MACS 
(1) does not rely on serial blood sampling, (2) takes account of 
clinical information (such as the nature of a patient’s symptoms 
and ECG findings), which clinicians are unlikely to ignore in 
practice, (3) risk stratifies undifferentiated patients with possible 
cardiac chest pain without the need for prior risk stratification 
(and could thus help to both ‘rule in’ and ‘rule out’ ACS) and (4) 
calculates the probability of ACS as a percentage. Future work 
could explore whether this function is informative and construc-
tive for clinicians and whether it could be used as part of a shared 
decision-making approach, which has previously been shown to 
be effective in this patient group.21
coNcLUsIoNs
Based on the observed recruitment rate, randomisation, data 
completeness and attrition, our findings seem to support the 
feasibility of a large trial comparing the MACS rule to standard 
care, although recruitment rate was suboptimal at one of our 
two trial sites. In this pilot trial, the use of the MACS decision 
rule also led to a greater proportion of patients being success-
fully discharged from the ED within 4 hours of arrival. However, 
a larger trial is still required to provide more precise estimates 
of safety outcomes.
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